key: cord-0810013-u8nao5o6
authors: younes, m.; hamze, k.; nassar, h.; makki, m.; Ghaddar, M.; Nguewa, p.; abdel sater, f.
title: Emergence and fast spread of B.1.1.7 lineage in Lebanon.
date: 2021-01-26
journal: nan
DOI: 10.1101/2021.01.25.21249974
sha: e3ce0609b6720d7b2ca96caec708a3e34662b3c0
doc_id: 810013
cord_uid: u8nao5o6

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a rapid spread emerging disease. Recently, a new variant of this virus called SARS-CoV-2 VOC 202012/01 (or B.1.1.7 lineage), described in the United Kingdom (UK), has become highly prevalent in several countries. Its rate of transmission has been estimated to be greatly higher. B.1.1.7 lineage harbors 23 mutations co-existed for the first time in the same variant. Herein, we are interested only by the deletion mutation {Delta}H69/{Delta}V70 in the spike protein. In the UK they were able to identify the increase of this new variant through the increase in the false negative result for the spike target of a three-target RT-PCR assay from Thermo Fisher Scientific (TaqPath kit). Later, the manufacturer announced that this false negative result is because of the deletion {Delta}H69/{Delta}V70 in the area targeted by the TaqPath Kit. Furthermore, The European CDC recommended that the use of this kit help to track the new variant. Genome sequencing is the gold method to confirm the new variant, but observational studies provide also stronger evidence if similar models are observed in multiple countries, especially when randomized studies are not possible. In Lebanon, the highest number of confirmed cases were reported in first week of 2021. In the present study, we show the emergence and the fast spreading of the new variant in Lebanon and a relationship between SARS-CoV-2 transmission intensity and the frequency of the new variant during the first twelve days of January.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was, and remains, the rapid spread emerging disease of the year. 1, 2 Recently, a new variant of this virus called SARS-CoV-2 VOC 202012/01 (or B.1.1.7) has been described in the United Kingdom (UK). It has become highly prevalent in parts of the UK, and is emerging in other countries. This variant was predicted to potentially be 50 to 70% more rapidly transmissible than other SARS-COV-2 variants circulating in the UK. 3 The analysis of Sequences showed that the new variant had accumulated a large number of mutations that together caused 17 amino acid changes in the virus' proteins. This variant was defined by eight mutations in spike protein while the others occurred in other regions of the genome, such as in the orf1-ab, orf8, and nucleocapsid (N) genes. One of spike mutations was 69-70del, a deletion in the S1 N-terminal domain NTD, that was found in a patient (Cambridge, U.K.), seemed to allow the virus to evade the immune system. 4 This mutation increased infectivity of Spike by two fold. While the other mutations in spike protein were deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H.

Recently, the European CDC recommended that multi-target RT-PCR assays that included an S gene target affected by the deletions could be used as a signal for the presence of the 69-70del mutation for further investigation and could be helpful to track these mutant variants. 6 Multi-target RT-PCR tests using S gene regions impacted by the 69-70del mutation are quicker and cheaper than sequencing especially, if sequencing capacity is limited. The Applied Biosystems™ TaqPath™ COVID-19 assay allows the detection of this mutation. 6 It was shown that in a patient infected with a variant harboring the 69-70del mutation, there will be an S gene "drop out". The sequencing of diagnostic PCR amplicon products from S gene dropout samples showed that the S gene target contained the 6-nucleotide deletion (21,765-21,770) leading to the Δ69-70 deletion in the middle of the amplicon. Those authors inferred the S gene dropout must be due to a failure of the qPCR probe to bind as a result of the Δ69-70. 7 Since February, SARS-COV-2 emerged in Lebanon and recently we have observed rapid spread of COVID-19 through the country. On December 21, the first case of the new variant was reported in Lebanon in a traveler on a flight coming from London. The Lebanese government confirmed . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.25.21249974 doi: medRxiv preprint highest amount of confirmed cases was recorded in the first week of 2021. They imposed a countrywide lockdown to combat the spread of COVID-19. In the present study, we show the emergence and the fast spreading of the new variant in Lebanon.

Samples were collected in Molecular labs at Bahman Hospital and Beirut Cardiac Institute. All patients or (guardians) provided written and signed informed consents. The study was conducted between December 9, 2020 and January 12, 2021. Nasopharyngeal swab samples were collected from 11657 patients. All PCR tests were performed using Applied Biosystems™ TaqPath™ COVID-19 assay. 2218 of tested patients were reported as positive.

Viral RNA from Nasopharyngeal swab were extracted, 200 µL of VTM were used for RNA purification. RNA was extracted from the clinical samples on Kingfisher flex purification system Thermo Fisher using MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit (Thermo fisher).

Reactions were performed in a 20-µL final volume reaction containing 5 µL of extracted RNA, rRT-PCR was performed using QuantStudio 5 real-time PCR detection system (Thermo fisher) and

TaqPath 2019-nCoV real-time PCR kit (Thermo fisher), which targeted the RdRP, N and Spike genes of SARS-CoV-2. Positive samples were retested by using Kylt ® SARS-CoV-2 Complete RTU (AniCon Labor GmbH Kylt ® ) which targeted the IP4 and Spike genes.

In December 9, a local patient was diagnosed as COVID -19 positive patient by PCR using TaqPath 2019-nCoV real-time PCR kit. RDRP and N genes of SARS-COV-2 were detected with a Ct value 18 while S gene was not detected. Two days later, the same profile was also detected in two patients from the same family in our laboratory. The 3 samples were retested using Kylt® SARS-CoV-2

Complete RTU, the results showed a detection of IP4 and Spike target genes. These observations showed that S gene may be affected by the same mutation in these 3 samples. In December 14, the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. Cases have been found in Iceland, Denmark, the Netherlands, Italy and Belgium and recently in France. In the present study, and during this ongoing COVID-19 pandemic and the emergence of multiple viral variants, we illustrate the emergence and the fast spreading of the new variant in Lebanon from December 9. Such an analysis will be carried to measure the frequency of mutations in our community; then, to determine its local transmission in Lebanon. Based on its spreading, we believe that the new variant will be the most common variant around the world.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Molecular Evolution of Human Coronavirus Genomes

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. medRxiv

Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom

Thermo Fisher's COVID-19 tests: designed with virus mutations in mind

Two-step strategy for the identification of SARS-CoV-2 variants co-occurring with spike deletion H69-V70